Alexion Pharmaceuticals Inc., of Cheshire, Conn., said the National Institute of Health and Clinical Excellence (NICE) Highly Specialized Technologies Evaluation Committee has reaffirmed the clinical value of the company's Soliris (eculizumab) for the treatment of atypical hemolytic uremic syndrome and the lack of other effective therapies, and has issued a recommendation that it be nationally commissioned for all patients suffering from the severe and life-threatening genetic disorder.